Raising the bar in ulcerative colitis management.
Fabrizio Fanizzi1, Mariangela Allocca1, Gionata Fiorino2
1Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
Therapeutic Advances in Gastroenterology
|November 27, 2024
Summary
Ulcerative colitis (UC) management is evolving towards personalized, treat-to-target strategies. New therapies and objective parameters aim to improve patient outcomes and control this chronic inflammatory bowel disease.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease with increasing global incidence and prevalence.
- Current UC management involves various strategies, but challenges remain due to new drug development and lack of specific guidelines.
- The shift towards personalized medicine in UC aims to tailor treatment based on individual patient profiles.
Purpose of the Study:
- To review current and emerging therapeutic strategies for managing ulcerative colitis (UC).
- To discuss the role of personalized medicine and treat-to-target approaches in optimizing UC treatment.
- To highlight the potential of novel molecular targets and dual-targeted therapies in achieving UC remission.
Main Methods:
- Comprehensive literature review of recent advancements in UC treatment.
- Analysis of clinical, endoscopic, biochemical, histological, ultrasonographic, and molecular parameters for UC management.
- Evaluation of personalized and treat-to-target strategies, including dual-targeted therapy.
Main Results:
- Personalized medicine and treat-to-target strategies are becoming central to UC management.
- Objective parameters like histological, ultrasonographic, and molecular targets enhance treatment efficacy.
- Dual-targeted therapy presents a promising option for refractory UC cases.
Conclusions:
- Optimizing UC management requires a personalized, treat-to-target approach incorporating diverse objective parameters.
- Emerging therapies and strategies aim to improve disease control and patient outcomes in ulcerative colitis.
- Further research into novel therapeutic targets and combination therapies is crucial for advancing UC care.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
01:29Inflammatory Bowel Disease IV: Pharmacological Management
113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
113
01:21Inflammatory Bowel Disease V: Surgical Management
121
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
121
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
317
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
317
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142